Defying Darkness: Confronting Wet AMD's Threat to Vision, Preserving Independence, and Elevating Quality of Life After 50

Wet age-related macular degeneration (AMD) holds a significant position as a leading cause of severe vision loss in individuals aged 50 and above. The condition primarily affects the central vision, a crucial component for tasks requiring sharp visual acuity. Given that central vision is essential for activities such as reading, recognizing faces, and driving, the impact of wet AMD on daily life can be profound. Loss of central vision not only hampers an individual's independence but also diminishes overall quality of life, as it impedes the ability to perform routine tasks critical for maintaining autonomy and engagement in various aspects of daily living.

Access Full Report at https://www.databridgemarketresearch.com/jp/reports/netherlands-wet-age-related-macular-degeneration-amd-market

Data Bridge Market Research analyses the Netherland Wet Age-Related Macular Degeneration (AMD) Market, which was USD 107.5 million in 2022, and it will grow up to USD 181.9 million by 2030 and is expected to undergo a CAGR of 6.8% during the forecast period of 2023 to 2030. The aging population in the Netherlands is a significant driver for the wet age-related macular degeneration (AMD) market, as the prevalence of AMD increases with age.

Key Findings of the Study

Increasing disease awareness campaigns is expected to drive the market's growth rate

In the Netherlands wet age-related macular degeneration (AMD) market, heightened disease awareness campaigns play a pivotal role as a driver. Increased public awareness regarding the symptoms, risk factors, and available treatments for wet AMD fosters early detection and prompt intervention. This heightened awareness not only improves patient outcomes by facilitating timely medical attention but also positively influences market dynamics. As individuals become more informed, there is a potential for a rise in patient consultations, diagnostic procedures, and treatment uptake, thereby driving market growth in the field of wet AMD.

Report Scope and Market Segmentation

Segment Analysis:

The Netherland wet age-related macular degeneration (AMD) market is segmented on the basis of drug class, product, age group, disease type, stages, end-user and distribution channel.

• Based on drug class, the Netherland wet age-related macular degeneration (AMD) market is segmented into monoclonal antibodies, benzoporphyrin derivative, and others
• On the basis of product, the Netherland wet age-related macular degeneration (AMD) market is segmented into biologics and biosimilar
• On the basis of age group, the Netherland wet age-related macular degeneration (AMD) market is segmented into 60–80 years, above 80 years, and 40–59 years
• On the basis of disease type, the Netherland wet age-related macular degeneration (AMD) market is segmented into wet AMD, and dry AMD
• On the basis of stages, the Netherland wet age-related macular degeneration (AMD) market is segmented into early AMD, intermediate AMD, advanced AMD, and no AMD
• On the basis of end-user, the Netherland wet age-related macular degeneration (AMD) market is segmented into hospitals, homecare, specialty clinics, and others
• On the basis of distribution channel, the Netherland wet age-related macular degeneration (AMD) market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy

Major Players

Data Bridge Market Research recognizes the following companies as the major Netherland wet age-related macular degeneration (AMD) market players in Netherland wet age-related macular degeneration (AMD) market are Loop Road Holdings LLC (U.S.), Old Saw Mill Holdings LLC (U.S.), OSMR LLC (U.S.), Regeneron Capital International B.V. (Netherlands) and Regeneron International Limited (Ireland)

Market Developments

• In February 2023, Apellis Pharmaceuticals, Inc. achieved a noteworthy feat with the U.S. Food and Drug Administration (FDA) approval of SYFOVRE (pegcetacoplan injection). This approval is significant for its indication in the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), offering new hope in managing this specific manifestation of AMD
• In September 2021 as Samsung Bioepis Co., Ltd., and Biogen Inc. received approval from the U.S. Food and Drug Administration (FDA) for Byooviz (ranibizumab-nuna). This marked a pivotal moment in the treatment landscape for neovascular (wet) age-related macular degeneration (AMD), showcasing the commitment to advancing therapeutic options
• In June 2021, Mosaic Biosciences and Ocular Therapeutix embarked on a strategic research collaboration aimed at developing a novel drug specifically designed for the treatment of patients suffering from dry age-related macular degeneration (AMD). This collaboration underscores the industry's ongoing efforts to address unmet medical needs and advance innovative solutions for AMD patients, potentially offering new therapeutic options in the future
• In February 2020, Novartis celebrated a milestone as the European Commission granted approval for Beovu (brolucizumab) injection, marking a breakthrough in wet age-related macular degeneration (AMD) treatment. Beovu, the first anti-VEGF (vascular endothelial growth factor) treatment to secure EC approval, demonstrated superior resolution of retinal fluid, emphasizing its efficacy in managing AMD

For more detailed information about the Netherland wet age-related macular degeneration (AMD) market report, click here – https://www.databridgemarketresearch.com/jp/reports/netherlands-wet-age-related-macular-degeneration-amd-market